Medical needles are used in mini-invasive percutaneous procedures and are deep-tissue inserted. ARC technology adds a mechanical option to medical needles allowing the correction of its trajectory and thus better reach the targeted tissue. Its main applications are biopsy and cancerous lesion treatment.

Nouvelles résines pour améliorer la protection balistique. Résines photopolymérisables rapidement sur les tissus d'aramide permettant la protection contre les balles et les fragments des véhicules et des personnes. Sans composés organiques volatils, le matériau préserve la santé des utilisateurs. Particulièrement adaptée aux véhicules blindés pour un coût d'équipements et d'utilisation avantageux.

New-infrared coating and implantable materials used as medical biosensors. Targeted applications for this new functionalized biomaterial: diagnostic detection for inflammatory and infectious processes, monitoring of patients suffering from chronic inflammatory diseases, monitoring of patients during or after surgical interventions

Potent Mn contrast agent ligand used for MRI. We develop Bispidine-based Mn2+ contrast agents with higher stability and relaxivity than standards, providing a safer alternative to Gadolinium contrast agents.

Small molecule (NCE) agonist of sigma1 receptor for the treatment of several neurodegenerative diseases. 2 chemical series, protected by 2 patents, highly selective and affine. Preliminary in-vivo data available on Alzheimer's, ALS (amyotrophic lateral sclerosis) and CIAS (cognitive impairement associated with schizophrenia) models.

Development of new photopolymerisable formulations (under UV or near-infrared LED light) for epoxy-amines resins. These formulations allow a polymerisation within minutes instead of hours, at room temperature without the necessity of thermal cure. Their application is in various fields and markets, such as composites, adhesives etc.

New gene therapy to treat Fragile X syndrome by targeting DGKk, new innovative therapeutic target validated in human tissues by the research team. We generated a first in-vivo proof of concept of DGKk gene therapy and patented the approach.

New antibody fragments for the treatment of thrombosis (stroke, thrombotic purpura, coronary syndrome...). Our approach is directed against a platelet receptor that is not currently targeted by commercially available products, and prevents thrombus formation with a reduced bleeding risk.

Human monoclonal antibodies with great neutralizing properties against BK virus. BKV infection causes BKV-associated nephropathy (BKVAN) in kidney transplant recipients, which leads to graft loss or urothelial carcinoma, but can also lead to hemorrhagic cystitis in bone marrow transplant recipients. Our lead antibodies have the ability to be best in class and neutralize BKV with improved efficacy.

New target and approach for the treatment of melanoma. Our technology aims at decreasing the expression of a novel long non-coding RNA that has been shown to be essential for the survival and proliferation of melanoma cancer cells using antisense oligonucleotides.